Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
This report summarizes the association between MELTF and lung adenocarcinoma. The evidence originates from multi‐patient genomic studies in young never‑smoker patients with lung adenocarcinoma (PMID:29667179). MELTF was identified as one of several candidate genes in a cohort of 36 patients, highlighting its potential involvement in the disease, although the gene was reported in a multi‐gene screen without extensive variant-level or segregation data.
Genetic evidence is derived from studies that employed whole genome sequencing and gene panel analysis to profile genomic alterations in lung adenocarcinoma. In these analyses, MELTF has been recurrently observed among a set of germline alterations. However, specific pathogenic variants for MELTF have not been detailed, and no explicit segregation analysis involving additional affected relatives was conducted (PMID:29667179).
No definitive HGVS‑formatted variant has been reported for MELTF in the context of lung adenocarcinoma. The available evidence does not include a discrete coding change for MELTF, and as such, the reported variant list remains empty. This represents a gap in the genetic evidence that will require further investigation.
Functional studies specific to MELTF in lung adenocarcinoma are currently lacking. Although high‑throughput correlative analyses, such as the plasma cell signature study, have evaluated gene expression patterns in lung adenocarcinoma (PMID:37814076), direct functional assays or mechanistic experiments validating the role of MELTF in tumorigenesis have not been published.
There is no reported conflicting evidence directly challenging the association between MELTF and lung adenocarcinoma. However, the overall support is limited by the absence of robust segregation data, detailed variant characterization, and targeted functional validation.
In conclusion, while MELTF has been recurrently identified in genomic studies of lung adenocarcinoma, the absence of detailed variant evidence, segregation studies, and direct functional assays restricts the clinical validity to a Limited level. Additional investigations are required to confirm the pathogenic role of MELTF in lung adenocarcinoma and to improve its utility in diagnostic decision‑making and commercial applications.
Key Take‑home Sentence: Despite its recurrent identification in sequencing studies, the clinical utility of MELTF in lung adenocarcinoma remains limited until further variant‐specific and functional data are available.
Gene–Disease AssociationLimitedBased on a single multi‑patient study of 36 never‑smoker lung adenocarcinoma patients (PMID:29667179) where MELTF was identified among other candidate genes without in‑depth variant or segregation data. Genetic EvidenceLimitedMELTF has been recurrently observed in genomic screens of lung adenocarcinoma; however, the lack of discrete pathogenic variants and segregation information curtails robust genetic validation (PMID:29667179). Functional EvidenceLimitedThere are no direct functional assays linking MELTF to lung adenocarcinoma, with existing data limited to correlative high‑throughput studies (PMID:37814076). |